A groundbreaking shift in type 2 diabetes treatment could be a game-changer for millions, offering hope and a chance at a healthier future. The National Institute for Health and Clinical Excellence (NICE) has released new guidelines that could save thousands of lives and revolutionize diabetes care.
Imagine a future where people with type 2 diabetes not only live longer but also enjoy a better quality of life. That's the promise of these new recommendations, which put the individual at the center of treatment decisions.
The Power of Early Intervention
NICE's final guidance, published recently, recommends offering a type of medicine called an SGLT-2 inhibitor, or 'flozins', much earlier in the treatment journey. This simple change could have a massive impact. Analysis suggests that using these medicines earlier, along with introducing GLP-1 receptor agonists and tirzepatide for some, could prevent around 17,000 deaths over three years in the UK. These medicines reduce the risk of heart attacks, strokes, and kidney problems, which are major concerns for people with type 2 diabetes.
But here's where it gets controversial...
A New Approach to Treatment
Traditionally, people newly diagnosed with type 2 diabetes were started on metformin. However, the new NICE guidance suggests a shift. Most people should now be offered metformin alongside an SGLT-2 inhibitor from the beginning. It's a personalized approach, ensuring that each person works with their healthcare professional to find the best treatment suited to their unique needs and preferences.
SGLT-2 inhibitors are powerful tools. They help the kidneys remove excess sugar from the body, but their benefits go beyond blood sugar control. Research shows they protect the heart and kidneys, which is crucial as heart disease is the leading cause of death for those with type 2 diabetes.
The guidance also recommends a slow-release form of metformin, which is easier on the stomach and helps people stick to their treatment, especially if they experience side effects.
Ensuring Fair Access for All
NICE analyzed the records of almost 590,000 people and found a concerning trend. SGLT-2 inhibitors are not being prescribed equitably across all populations. Women, older people, and Black individuals often miss out on the care they need. The new guidance includes recommendations to monitor and address these disparities, ensuring everyone with type 2 diabetes has fair access to the best treatments.
This is a landmark moment, as Eric Power, interim director of the NICE guidelines center, explains:
"Our committee's rigorous review concluded that offering certain medicines earlier can prevent thousands of heart attacks, strokes, and cases of kidney failure. This keeps people healthier for longer and reduces the burden on NHS services."
Eric adds a sobering note:
"Troublingly, we found these life-saving medicines are under-prescribed to women, older people, and Black patients. Tackling health inequalities is core to our work, and these recommendations will ensure everyone gets fair access."
A Personalized Approach to Diabetes Care
The new guidance moves away from a one-size-fits-all approach. Instead, it offers tailored recommendations based on individual circumstances:
- People diagnosed with type 2 diabetes before age 40, who face a higher lifetime risk of heart and kidney problems, may benefit from adding GLP-1 receptor agonists (like semaglutide, dulaglutide, and liraglutide) or tirzepatide.
- Those living with obesity have specific recommendations that consider their unique needs.
- People with existing kidney disease or heart failure have tailored recommendations, with SGLT-2 inhibitors offering particular benefits for kidney and heart protection.
Douglas Twenefour, Head of Clinical at Diabetes UK, welcomes the guidance:
"This shift towards a personalized approach will ensure more people get the right treatment at the right time. Monitoring medicine uptake will help address the inequities in type 2 diabetes treatments and outcomes."
Expanding Access to Newer Medicines
The guidance also expands access to GLP-1 receptor agonists (like semaglutide, dulaglutide, and liraglutide) and tirzepatide. These medicines will now be recommended for people with type 2 diabetes who also have cardiovascular disease caused by blocked arteries (such as previous heart attacks or strokes). Around 810,000 more people could benefit from these medicines, which help manage blood sugar and protect the heart and kidneys.
The Importance of Healthy Living
While medicines are crucial, they are just one part of managing type 2 diabetes. Doctors and nurses should discuss diet, physical activity, and other healthy lifestyle changes alongside any prescribed treatments. Some people may even achieve diabetes remission through dietary and weight changes, as supported by the NHS Type 2 Diabetes Path to Remission Programme.
People with type 2 diabetes are encouraged to speak to their healthcare providers at their next diabetes follow-up appointment to understand how these changes may impact their treatment and overall health.
